NCT00703365 - Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

August 31, 2011

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG

Sorafenib and Gemcitabine

Sorafenib 400 mg po bid daily and Gemcitabine IV 1,000 mg/m2 on day 1,8, 15 of a 28-day cycle (up to 6 cycles), then followed by Sorafenib 400 mg po bid daily maintenance until disease progression.

Trial Locations (3)

10110

Horizon Regional Cancer Center, Bamrungrad Hospital, Sukhumvit

10330

Medical Oncology Unit, Chulalongkorn Hospital, Patumwan

10700

Department of Medicine, Siriraj Hospital, Bangkoknoi